Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · IEX Real-Time Price · USD
36.08
+0.66 (1.86%)
At close: Jul 26, 2024, 4:00 PM
36.81
+0.73 (2.02%)
After-hours: Jul 26, 2024, 5:28 PM EDT
Collegium Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 566.92 | 566.77 | 463.93 | 276.87 | 310.02 | 296.7 | Upgrade
|
| Revenue Growth (YoY) | 8.00% | 22.17% | 67.56% | -10.69% | 4.49% | 5.81% | Upgrade
|
| Cost of Revenue | 78.94 | 79.72 | 78.61 | 59.07 | 69.5 | 178.91 | Upgrade
|
| Gross Profit | 487.98 | 487.05 | 385.33 | 217.8 | 240.52 | 117.79 | Upgrade
|
| Selling, General & Admin | 148.42 | 150.71 | 141.59 | 118.96 | 113.83 | 116.45 | Upgrade
|
| Research & Development | - | - | 3.98 | 9.45 | 9.77 | 10.34 | Upgrade
|
| Depreciation & Amortization | 142.81 | 145.76 | 131.47 | 67.18 | 60.68 | 14.75 | Upgrade
|
| Operating Expenses | 291.23 | 296.47 | 277.04 | 195.59 | 184.28 | 141.54 | Upgrade
|
| Operating Income | 196.75 | 190.58 | 108.29 | 22.21 | 56.23 | -23.75 | Upgrade
|
| Interest Expense | -79.25 | -83.34 | -63.21 | -21.01 | -28.88 | -0.91 | Upgrade
|
| Interest & Investment Income | 17.36 | 15.62 | 1.05 | 0.01 | 0.23 | 1.94 | Upgrade
|
| EBT Excluding Unusual Items | 134.86 | 122.85 | 46.12 | 1.2 | 27.58 | -22.72 | Upgrade
|
| Merger & Restructuring Charges | -4.95 | -15.12 | -70.18 | -4.58 | - | - | Upgrade
|
| Asset Writedown | - | - | -4.79 | - | - | - | Upgrade
|
| Legal Settlements | - | -8.5 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | -23.5 | - | - | - | - | Upgrade
|
| Pretax Income | 129.91 | 75.73 | -28.85 | -3.37 | 27.58 | -22.72 | Upgrade
|
| Income Tax Expense | 36.62 | 27.58 | -3.85 | -74.89 | 0.83 | - | Upgrade
|
| Net Income | 93.29 | 48.16 | -25 | 71.52 | 26.75 | -22.72 | Upgrade
|
| Net Income to Common | 93.29 | 48.16 | -25 | 71.52 | 26.75 | -22.72 | Upgrade
|
| Net Income Growth | - | - | - | 167.33% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 33 | 34 | 34 | 35 | 34 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 44 | 42 | 34 | 41 | 35 | 33 | Upgrade
|
| Shares Change (YoY) | 28.18% | 23.53% | -17.58% | 16.77% | 5.07% | 1.52% | Upgrade
|
| EPS (Basic) | 2.81 | 1.43 | -0.74 | 2.05 | 0.78 | -0.68 | Upgrade
|
| EPS (Diluted) | 2.32 | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 | Upgrade
|
| EPS Growth | - | - | - | 144.25% | - | - | Upgrade
|
| Free Cash Flow | 308.16 | 274.29 | 122.61 | 101.61 | 88.4 | 21.35 | Upgrade
|
| Free Cash Flow Per Share | 7.07 | 6.56 | 3.62 | 2.48 | 2.51 | 0.64 | Upgrade
|
| Gross Margin | 86.08% | 85.93% | 83.06% | 78.66% | 77.58% | 39.70% | Upgrade
|
| Operating Margin | 34.71% | 33.63% | 23.34% | 8.02% | 18.14% | -8.00% | Upgrade
|
| Profit Margin | 16.46% | 8.50% | -5.39% | 25.83% | 8.63% | -7.66% | Upgrade
|
| Free Cash Flow Margin | 54.36% | 48.40% | 26.43% | 36.70% | 28.51% | 7.19% | Upgrade
|
| EBITDA | 343.16 | 339.83 | 242.44 | 91.12 | 117.78 | -8.27 | Upgrade
|
| EBITDA Margin | 60.53% | 59.96% | 52.26% | 32.91% | 37.99% | -2.79% | Upgrade
|
| D&A For EBITDA | 146.41 | 149.26 | 134.15 | 68.92 | 61.55 | 15.48 | Upgrade
|
| EBIT | 196.75 | 190.58 | 108.29 | 22.21 | 56.23 | -23.75 | Upgrade
|
| EBIT Margin | 34.71% | 33.63% | 23.34% | 8.02% | 18.14% | -8.00% | Upgrade
|
| Effective Tax Rate | 28.19% | 36.41% | - | - | 3.01% | - | Upgrade
|
| Advertising Expenses | - | 7.41 | 11.74 | 4.19 | 5.37 | 9.53 | Upgrade
|
Source: S&P Capital IQ. Standard template.